Teva Pharmaceutical Industries (TEVA) Accounts Payables (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Accounts Payables across 18 years of filings, most recently posting $2.6 billion for Q1 2026.

• Quarterly Accounts Payables rose 13.36% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 13.36% YoY) and the FY2025 annual result came in at $2.5 billion, up 14.89% from the prior year.
• Accounts Payables improved to $2.6 billion in Q1 2026, from $2.5 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $2.6 billion in Q4 2023 and troughed at $1.6 billion in Q3 2022.
• A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 39.45% — and 2024, when it decreased 15.33%.
• Tracing TEVA's Accounts Payables over 5 years: stood at $1.9 billion in 2022, then jumped by 37.89% to $2.6 billion in 2023, then retreated by 15.33% to $2.2 billion in 2024, then increased by 14.89% to $2.5 billion in 2025, then gained by 2.57% to $2.6 billion in 2026.
• Business Quant data shows TEVA's Accounts Payables at $2.6 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.4 billion in Q3 2025.